Yuejun Luo

830 total citations · 1 hit paper
19 papers, 469 citations indexed

About

Yuejun Luo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yuejun Luo has authored 19 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yuejun Luo's work include Cancer Immunotherapy and Biomarkers (8 papers), Cancer-related molecular mechanisms research (6 papers) and Lung Cancer Research Studies (6 papers). Yuejun Luo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Cancer-related molecular mechanisms research (6 papers) and Lung Cancer Research Studies (6 papers). Yuejun Luo collaborates with scholars based in China, United States and Pakistan. Yuejun Luo's co-authors include Nan Sun, Peng Wu, Jié He, Yuxin Yao, Xiaohui Zi, Guochao Zhang, Chaoqi Zhang, Jie He, Nan Sun and Zhihui Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Frontiers in Immunology and Carcinogenesis.

In The Last Decade

Yuejun Luo

18 papers receiving 469 citations

Hit Papers

The potential role of N7-methylguanosine (m7G) in cancer 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The potential role of N7-methylguanosine (m7G) in cancer
    2022 167 citations Yuejun Luo, Yuxin Yao et al. Journal of Hematology & Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuejun Luo China 11 335 217 151 113 60 19 469
Chenglai Dong China 7 401 1.2× 260 1.2× 53 0.4× 79 0.7× 20 0.3× 10 482
Xinde Ou China 7 237 0.7× 199 0.9× 128 0.8× 88 0.8× 54 0.9× 8 389
Cristina Borzi Italy 12 275 0.8× 242 1.1× 63 0.4× 94 0.8× 12 0.2× 18 413
Xufan Li China 7 397 1.2× 317 1.5× 51 0.3× 50 0.4× 14 0.2× 12 447
Mark G. Woodcock United States 7 222 0.7× 184 0.8× 26 0.2× 104 0.9× 30 0.5× 13 349
Yinghan Su China 9 204 0.6× 136 0.6× 31 0.2× 71 0.6× 17 0.3× 11 305
Wenlan Yang China 7 274 0.8× 163 0.8× 34 0.2× 25 0.2× 28 0.5× 9 367
Yongfeng Yu China 9 197 0.6× 150 0.7× 91 0.6× 90 0.8× 16 0.3× 19 312
Kaiqing Wu China 4 332 1.0× 208 1.0× 47 0.3× 76 0.7× 12 0.2× 4 399
Jinchang Pan China 11 588 1.8× 546 2.5× 55 0.4× 36 0.3× 38 0.6× 20 692

Countries citing papers authored by Yuejun Luo

Since Specialization
Citations

This map shows the geographic impact of Yuejun Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuejun Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuejun Luo more than expected).

Fields of papers citing papers by Yuejun Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuejun Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuejun Luo. The network helps show where Yuejun Luo may publish in the future.

Co-authorship network of co-authors of Yuejun Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Yuejun Luo. A scholar is included among the top collaborators of Yuejun Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuejun Luo. Yuejun Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Liu, Chengming, Yuxin Yao, Yuejun Luo, et al.. (2024). Unveiling the role of Pleckstrin-2 in tumor progression and immune modulation: insights from a comprehensive pan-cancer analysis with focus on lung cancer. Molecular Biomedicine. 5(1). 59–59. 1 indexed citations
2.
Luo, Yuejun, Yuxin Yao, Peng Wu, et al.. (2023). Profile of treatment-related adverse events of PD-1 blockade-based therapies in advanced esophageal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 183. 103922–103922. 2 indexed citations
3.
Li, Dongyu, Chengming Liu, Yuejun Luo, et al.. (2023). Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs. Biomedicines. 11(4). 1141–1141. 3 indexed citations
4.
Wu, Peng, Zhihui Zhang, Zhaoyang Yang, et al.. (2022). Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer. Cancer Immunology Immunotherapy. 72(3). 617–631.
5.
Luo, Yuejun, Yuxin Yao, Peng Wu, et al.. (2022). The potential role of N7-methylguanosine (m7G) in cancer. Journal of Hematology & Oncology. 15(1). 63–63. 167 indexed citations breakdown →
6.
Sun, Nan, Yuejun Luo, Bo Zheng, et al.. (2022). A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma. Journal of Translational Medicine. 20(1). 332–332. 10 indexed citations
7.
8.
Zhang, Zhihui, Yuejun Luo, Chaoqi Zhang, et al.. (2021). An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer. Cancer Cell International. 21(1). 6 indexed citations
9.
Zhang, Guochao, Chaoqi Zhang, Nan Sun, et al.. (2021). Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China. Journal of Cancer Research and Clinical Oncology. 148(4). 943–954. 26 indexed citations
10.
11.
Zhang, Zhihui, Peng Wu, Chaoqi Zhang, et al.. (2021). Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer. Frontiers in Immunology. 12. 745769–745769. 6 indexed citations
12.
Zhang, Chaoqi, Yuejun Luo, Guochao Zhang, et al.. (2021). RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential. SHILAP Revista de lepidopterología. 11(9). e525–e525. 27 indexed citations
13.
Cai, Rui, Yuejun Luo, Ziyuan Wang, et al.. (2020). TUSC3 induces drug resistance and cellular stemness via Hedgehog signaling pathway in colorectal cancer. Carcinogenesis. 41(12). 1755–1766. 12 indexed citations
14.
Zhang, Chaoqi, Guochao Zhang, Nan Sun, et al.. (2020). Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma. EBioMedicine. 59. 102959–102959. 50 indexed citations
15.
Zhang, Chaoqi, Yuejun Luo, Zhen Zhang, et al.. (2020). Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes. Frontiers in Cell and Developmental Biology. 8. 580005–580005. 13 indexed citations
16.
Zhang, Chaoqi, Guochao Zhang, Zhihui Zhang, et al.. (2020). Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. Cancer Letters. 479. 31–41. 53 indexed citations
17.
Zhang, Chaoqi, Zhihui Zhang, Nan Sun, et al.. (2020). Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma. OncoImmunology. 9(1). 1824641–1824641. 38 indexed citations
18.
Zhang, Chaoqi, Rui Wang, Nan Sun, et al.. (2020). The combination of novel immune checkpoints HHLA2 and ICOSLG: A new system to predict survival and immune features in esophageal squamous cell carcinoma. Genes & Diseases. 9(2). 415–428. 7 indexed citations
19.
Xiao, Jie, Yuanyuan Tao, Yuejun Luo, et al.. (2020). Expression Analysis and Serodiagnostic Potential of Microneme Proteins 1 and 3 in Eimeria stiedai. Genes. 11(7). 725–725. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chenglai Dong Breakdown of academic impact, for papers by Xinde Ou Breakdown of academic impact, for papers by Cristina Borzi Breakdown of academic impact, for papers by Xufan Li Breakdown of academic impact, for papers by Mark G. Woodcock Breakdown of academic impact, for papers by Yinghan Su Breakdown of academic impact, for papers by Wenlan Yang Breakdown of academic impact, for papers by Yongfeng Yu Breakdown of academic impact, for papers by Kaiqing Wu Breakdown of academic impact, for papers by Jinchang Pan
Rankless by CCL
2026